Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996553622> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2996553622 endingPage "1180" @default.
- W2996553622 startingPage "1172" @default.
- W2996553622 abstract "Background: Progress in the developments of pyrimidine-coumarin moiety as an IDO inhibitor is still continuing with an outcome of the good scaffold as pyrimidine as well as coumarin individually for anticancer activity. Hence we proposed a suitable approach for the synthesis of pyrimidinecoumarin moieties in a combined form from the results of docking studies. Objective: As part of our ongoing research towards the development of novel cytotoxic agents, the synthesis and cytotoxic activity of a series of N'-(1-(6-methyl-2-oxo/thioxo-4-sub phenyl-1,2,3,4- tetrahydropyrimidin-5-yl)vinyl)-2-oxo-2H-chromene-3-carbohydrazide derivatives are discussed in this study. Methods: N'-(1-(6-methyl-2-oxo/thioxo-4-sub phenyl-1,2,3,4-tetrahydropyrimidin-5-yl)vinyl)-2-oxo- 2H-chromene-3-carbohydrazide derivatives were designed, synthesized and evaluated for cytotoxic activity. The structures were confirmed by IR, 1H NMR, C13NMR, Mass spectroscopy. All the synthesized compounds were evaluated using in vitro MTT assay against HeLa and HepG2 cell lines. Results: Compound 6g showed inhibitory activity against IDO with IC50 values at nanomolar range in docking studies and compounds 6g and 6f also showed significant cytotoxic activity on human cancer cell lines like HepG2 and HeLa using in vitro MTT assay. Conclusion: This work showed that the coumarin containing pyrimidine derivatives are found to be the most potent against IDO through docking studies and cytotoxic against cell lines compared with cisplatin. This might give the information for the development of new series of compounds against IDO." @default.
- W2996553622 created "2019-12-26" @default.
- W2996553622 creator A5070482744 @default.
- W2996553622 creator A5078344170 @default.
- W2996553622 date "2020-11-10" @default.
- W2996553622 modified "2023-09-23" @default.
- W2996553622 title "Development of New IDO Inhibitors with Coumarin Pyrimidine Scaffolds as the Potential Anti Cancer Agents" @default.
- W2996553622 cites W1983050089 @default.
- W2996553622 cites W2079515425 @default.
- W2996553622 cites W2095232605 @default.
- W2996553622 cites W2095808484 @default.
- W2996553622 cites W2096973536 @default.
- W2996553622 cites W2155208683 @default.
- W2996553622 cites W2220882815 @default.
- W2996553622 cites W2265159613 @default.
- W2996553622 cites W2529484692 @default.
- W2996553622 cites W2603893805 @default.
- W2996553622 cites W2604324612 @default.
- W2996553622 cites W2784361372 @default.
- W2996553622 doi "https://doi.org/10.2174/1573407216666191216154856" @default.
- W2996553622 hasPublicationYear "2020" @default.
- W2996553622 type Work @default.
- W2996553622 sameAs 2996553622 @default.
- W2996553622 citedByCount "1" @default.
- W2996553622 countsByYear W29965536222022 @default.
- W2996553622 crossrefType "journal-article" @default.
- W2996553622 hasAuthorship W2996553622A5070482744 @default.
- W2996553622 hasAuthorship W2996553622A5078344170 @default.
- W2996553622 hasConcept C141071460 @default.
- W2996553622 hasConcept C154317977 @default.
- W2996553622 hasConcept C159110408 @default.
- W2996553622 hasConcept C178790620 @default.
- W2996553622 hasConcept C185592680 @default.
- W2996553622 hasConcept C202751555 @default.
- W2996553622 hasConcept C21951064 @default.
- W2996553622 hasConcept C2776694085 @default.
- W2996553622 hasConcept C2777366897 @default.
- W2996553622 hasConcept C2777752497 @default.
- W2996553622 hasConcept C2778239845 @default.
- W2996553622 hasConcept C2779321679 @default.
- W2996553622 hasConcept C2780783641 @default.
- W2996553622 hasConcept C2781338262 @default.
- W2996553622 hasConcept C41685203 @default.
- W2996553622 hasConcept C55493867 @default.
- W2996553622 hasConcept C71240020 @default.
- W2996553622 hasConcept C71924100 @default.
- W2996553622 hasConceptScore W2996553622C141071460 @default.
- W2996553622 hasConceptScore W2996553622C154317977 @default.
- W2996553622 hasConceptScore W2996553622C159110408 @default.
- W2996553622 hasConceptScore W2996553622C178790620 @default.
- W2996553622 hasConceptScore W2996553622C185592680 @default.
- W2996553622 hasConceptScore W2996553622C202751555 @default.
- W2996553622 hasConceptScore W2996553622C21951064 @default.
- W2996553622 hasConceptScore W2996553622C2776694085 @default.
- W2996553622 hasConceptScore W2996553622C2777366897 @default.
- W2996553622 hasConceptScore W2996553622C2777752497 @default.
- W2996553622 hasConceptScore W2996553622C2778239845 @default.
- W2996553622 hasConceptScore W2996553622C2779321679 @default.
- W2996553622 hasConceptScore W2996553622C2780783641 @default.
- W2996553622 hasConceptScore W2996553622C2781338262 @default.
- W2996553622 hasConceptScore W2996553622C41685203 @default.
- W2996553622 hasConceptScore W2996553622C55493867 @default.
- W2996553622 hasConceptScore W2996553622C71240020 @default.
- W2996553622 hasConceptScore W2996553622C71924100 @default.
- W2996553622 hasIssue "8" @default.
- W2996553622 hasLocation W29965536221 @default.
- W2996553622 hasOpenAccess W2996553622 @default.
- W2996553622 hasPrimaryLocation W29965536221 @default.
- W2996553622 hasRelatedWork W11863419 @default.
- W2996553622 hasRelatedWork W17252590 @default.
- W2996553622 hasRelatedWork W22421320 @default.
- W2996553622 hasRelatedWork W23010048 @default.
- W2996553622 hasRelatedWork W23604527 @default.
- W2996553622 hasRelatedWork W25961052 @default.
- W2996553622 hasRelatedWork W26404334 @default.
- W2996553622 hasRelatedWork W31550863 @default.
- W2996553622 hasRelatedWork W4104980 @default.
- W2996553622 hasRelatedWork W10440690 @default.
- W2996553622 hasVolume "16" @default.
- W2996553622 isParatext "false" @default.
- W2996553622 isRetracted "false" @default.
- W2996553622 magId "2996553622" @default.
- W2996553622 workType "article" @default.